† http://techland.time.com/2013/11/14/the-25-best-inventions-of-the-year-2013/slide/the-artificial-pancreas/
* Terms and conditions apply
1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N Engl J Med. 2008;359:1464-1476. 2. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-320. 3. User evaluations. Data on file, Medtronic MiniMed, Inc. 4. CONTOUR® NEXT LINK meter meets ±10% accuracy vs. laboratory method for blood glucose concentrations, specifically: 99.2% of results within ±10% for blood glucose concentrations ≥4.2 mmol/L, and 100% of results within ±0.56 mmol/L accuracy vs. laboratory method for blood glucose concentrations <4.2 mmol/L. 5. Medtronic Canada proprietary market research Jan 2015 - Data on File. 6. Data on file from only voluntary CareLink® Personal Paradigm Veo™ Uploads available from May 1, 2011 to Sep 9, 2014 evaluated. Presented at “European Association for the Study of Diabetes (EASD)” CGM Roundtable September 2014. 7. Bergenstal RM, Klonoff DC, Garg SK. et al. N Engl J Med. July 18, 2013. 8. Enlite® Sensor Performance Addendum, Paradigm® Veo™ Algorithm, True Alert Rate for Predictive and Threshold for 3.89 mmol/L @ 30 minutes; CLSI Guidelines, Method 2. 9. Veeze HJ. et al Poster 136 ISPAD 2014 : Real-life performance evaluation of the New Generation Enlite® glucose sensor in patients with Diabetes Mellitus. 10. MiniMed® Veo™ insulin pump and CGM system user guide. May 7, 2014. 11. Corriveau EA, Durso PJ, Kaufman ED, et al. Effect of CareLink®, an internet based insulin pump monitoring system, on glycemic control in rural and urban children with type 1 diabetes mellitus. Pediatric Diabetes. 2008;9(Partii):360-366. 12. Reznik Y. Cohen O. Aronson R. et al, Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial. The Lancet 2014; published online July 3. Source : http://www.medtronicdiabetes.com/treatment-and-products/insulin-pump-therapy-type-2 13. https://www.medtronic-diabetes.co.uk/customer-support/insulin-pumps/important-safety-information MiniMed and Enlite are registered trademarks of Medtronic MiniMed, Inc. Veo, and Bolus Wizard are trademarks of Medtronic MiniMed, Inc. Medtronic CareLink and CareLink are registered trademarks of Medtronic, Inc. 14. Battelino T, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia DOI 10.1007/s00125-012-2708-9 15. Ly T. et al Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients With Type 1 Diabetes A Randomized Clinical Trial JAMA. 2013;310(12):1240-1247
All other product names and trademarks are the pro perty of their respective owners.
IPCCBHCP032015EN